Michael Leuchten

Stock Analyst at UBS

(2.54)

# 2,171

Out of 4,708 analysts

9

Total ratings

71.43%

Success rate

9.72%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General

Stocks Rated by Michael Leuchten

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NVO Novo Nordisk	Downgrades: Sell	n/a	$105.96	-	4	Jun 28, 2022
	AZN AstraZeneca	Upgrades: Buy	n/a	$64.64	-	4	Feb 25, 2021
	SNY Sanofi	Downgrades: Underweight	n/a	$47.01	-	1	Jan 23, 2018

Novo Nordisk

Jun 28, 2022

Downgrades: Sell

Price Target: n/a

Current: $105.96

Upside: -

AstraZeneca

Feb 25, 2021

Upgrades: Buy

Price Target: n/a

Current: $64.64

Upside: -

Sanofi

Jan 23, 2018

Downgrades: Underweight

Price Target: n/a

Current: $47.01

Upside: -